INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/GiftVerified data

Yan Ming reported CTKB

Director, CHIEF TECHNOLOGY OFFICER · Cytek Biosciences, Inc. · Common Stock

Side
G
Value
—
Shares
1.18M
Price
—
Executed
Mar 13, 2026
Disclosed
Mar 13, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Mar 13 executedMar 13, 2026 disclosed

CTKB · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
20/ 100 · ROUTINE
Methodology →
  • Transaction type+3 / 20

    Gift

  • Relative size+9 / 25

    No reported dollar value · 31.4% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CTKB

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    13.1K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$9,858
    2,111 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$33K
    7,062 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    29.0K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    7,363 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    6,320 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$7,010
    1,501 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$6,286
    1,346 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    6,162 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$25K
    5,382 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    21
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    11.8K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    57.2K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$8,303
    1,778 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    14.2K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$25K
    5,401 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    16.0K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    16.0K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    5,525 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$16K
    3,463 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    21
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    7,363 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001874041-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 13, 2026
    Published
    Mar 13, 2026
    Ingested by INSIDER
    Nov 5, 04:11 UTC
    Last re-read
    Nov 5, 04:11 UTC

    Extracted facts

    Filer
    Yan Ming
    Role
    Director, CHIEF TECHNOLOGY OFFICER
    Transaction
    GiftAs filed: “G”
    Asset
    Cytek Biosciences, Inc.
    Ticker
    CTKB
    Shares
    1.18M
    Price per share
    $0
    Execution date (reported)
    Mar 13, 2026
    Owned after transaction
    4.92M shares
    Days from execution to publication
    0

    What this establishes

    Yan Ming filed this Form 4 reporting a gift of CTKB on Mar 13, 2026. It became public on Mar 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CHIEF TECHNOLOGY OFFICER
    Yan Mingcik:0001874041
    Issuer
    Cytek Biosciences, Inc.cik:0001831915

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.